CN112852731A - 一种体外诱导造血干细胞向调节性t细胞分化的方法 - Google Patents
一种体外诱导造血干细胞向调节性t细胞分化的方法 Download PDFInfo
- Publication number
- CN112852731A CN112852731A CN202110308242.7A CN202110308242A CN112852731A CN 112852731 A CN112852731 A CN 112852731A CN 202110308242 A CN202110308242 A CN 202110308242A CN 112852731 A CN112852731 A CN 112852731A
- Authority
- CN
- China
- Prior art keywords
- cells
- regulatory
- hematopoietic stem
- cell
- sorting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003289 regulatory T cell Anatomy 0.000 title claims abstract description 103
- 238000000034 method Methods 0.000 title claims abstract description 33
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 28
- 230000001939 inductive effect Effects 0.000 title claims abstract description 22
- 238000000338 in vitro Methods 0.000 title claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims abstract description 104
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims abstract description 20
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims abstract description 20
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 19
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims abstract description 17
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 17
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims abstract description 17
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 17
- 210000004369 blood Anatomy 0.000 claims abstract description 17
- 239000008280 blood Substances 0.000 claims abstract description 17
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims abstract description 13
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims abstract description 13
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims abstract description 13
- 230000006698 induction Effects 0.000 claims abstract description 12
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 11
- 108090000172 Interleukin-15 Proteins 0.000 claims abstract description 11
- 108010002386 Interleukin-3 Proteins 0.000 claims abstract description 11
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 11
- 239000011886 peripheral blood Substances 0.000 claims abstract description 11
- 108010078233 Thymalfasin Proteins 0.000 claims abstract description 10
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims abstract description 10
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims abstract description 10
- 229960004231 thymalfasin Drugs 0.000 claims abstract description 10
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 claims abstract description 8
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 claims abstract description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 8
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 4
- 102000000646 Interleukin-3 Human genes 0.000 claims abstract description 4
- 230000001678 irradiating effect Effects 0.000 claims abstract 2
- 230000004069 differentiation Effects 0.000 claims description 35
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 18
- 239000002609 medium Substances 0.000 claims description 15
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 12
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 10
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 10
- 229930182555 Penicillin Natural products 0.000 claims description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 9
- MAYUCBCSAVDUKG-UHFFFAOYSA-N orthoacetic acid Chemical compound CC(O)(O)O MAYUCBCSAVDUKG-UHFFFAOYSA-N 0.000 claims description 9
- 229940049954 penicillin Drugs 0.000 claims description 9
- 229960005322 streptomycin Drugs 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 7
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 238000010186 staining Methods 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 229960002989 glutamic acid Drugs 0.000 claims description 5
- 229940054269 sodium pyruvate Drugs 0.000 claims description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 4
- 239000003797 essential amino acid Substances 0.000 claims description 4
- 235000020776 essential amino acid Nutrition 0.000 claims description 4
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 13
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 4
- -1 atRA Proteins 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 23
- 239000011324 bead Substances 0.000 description 15
- 238000002054 transplantation Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 8
- 239000003018 immunosuppressive agent Substances 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006058 immune tolerance Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 229940124589 immunosuppressive drug Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 210000002501 natural regulatory T cell Anatomy 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 210000002602 induced regulatory T cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000003317 double-positive, alpha-beta immature T lymphocyte Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明提供一种体外诱导造血干细胞向调节性T细胞分化的方法,具体步骤如下:第一步,采集血液;第二步,对血液进行分离、分选获得到CD34+、CD38+和CD39+;第三步,选择第二步剩余细胞制备DC细胞;第四步,对第二步中分选得到的细胞进行第一次诱导;第五步,进行第二次诱导;第六步,进行第三次诱导得到CD4+、CD25+、Foxp3+调节性T细胞。本发明的有益效果是:本发明采用人外周血中分离CD34+、CD38+和CD39+细胞,加入胸腺素α1、IL‑2、IL‑3、IL‑15、TGF‑β、atRA、TRAF6以及辐照后DC细胞,最终诱导人的造血干细胞成为具有免疫抑制功能的调节性T细胞。
Description
技术领域
本发明涉及生物技术领域,更具体地说涉及一种体外诱导造血干细胞向调节性T细胞分化的方法。
背景技术
器官移植等现已成为治疗终末期器官衰竭的唯一有效手段。器官移植术后患者必须终身服用免疫抑制药物来预防移植排斥和移植物抗宿主病(GVHD)等多种移植免疫疾病。长期服用免疫抑制药物可诱发感染,肿瘤复发,慢性移植物失功能等。为了减少以上副作用,各国的器官移植中心均尝试停用免疫抑制药物,但是药物的停用亦有可能导致肝肾功能异常,代谢紊乱乃至慢性排斥等疾病,停药成功者均为个例报道。因此,寻求能有效诱导移植物内免疫平衡和自我耐受的治疗策略,进而减少或停用免疫抑制药物已成为移植领域的热点课题。
调节性T细胞(Tregs)是一种具有免疫调节功能的T细胞亚群,它参与维持机体免疫平衡。Tregs包括诱导型Tregs(iTregs)和自然Tregs(nTregs),多项体内外研究已显示,Tregs能够通过抑制T细胞,B细胞,NK细胞和树突状细胞等多种免疫细胞的激活、扩增、分化以及效应功能发挥免疫抑制作用。多项报道表明Tregs在肝脏免疫的调节中发挥重要作用,Taylor等报道IL-2预处理可抑制小鼠肝纤维化,减轻肝内炎症细胞浸润,其机制与抑制肝内Th1、Th2,增加Tregs有关,提示Tregs对肝脏免疫损伤具有保护作用;Kinsey发现尾静脉注射Tregs可显著缓解免疫损伤。
近年来,Brouard等报道撤除免疫抑制剂(>1年)的肾移植患者外周血内存在高水平的Tregs;日本的移植中心采用供体抗原富集后单核淋巴细胞成功诱导移植免疫耐受,整体结果为Tregs诱导器官移植免疫耐受提供了强有力的支撑;Pu等于2007年亦报道 Tregs可有效诱导大鼠肝脏移植模型的免疫耐受,2014年在中国南京启动了世界首例自体Tregs诱导肝移植术后免疫耐受的临床研究。至今共实施Tregs治疗17例,5例进入临床撤药状态,进一步证实Tregs在移植免疫耐受中的核心作用。
目前有关调节性T细胞的应用仍受到以下条件的限制:自然产生的Tregs(天然Treg)数量少。天然Tregs在动物体内约占胸腺和外周血CD4+的5%-10%,而在正常人体中仅仅 1-2%的CD25bright细胞具有免疫抑制功能。因此,缺乏足够数量的Tregs制约着临床的应用的可行性;2)患者Tregs存在扩增功能和免疫调控功能缺陷,细胞功能异常直接影响调节性T细胞治疗的疗效。
现有的少量临床研究中,Tregs主要由幼稚T细胞在包被CD3/CD28的磁珠和IL-2的刺激下来诱导扩增获得,虽然这种扩增方式可以获得一定量的细胞,但是这种技术也有它的弊端:1)培养易导致细胞Foxp3降低,2)扩增时间越久,Treg功能越低,3)培养成本昂贵。因此寻找新的调节性T细胞来源并建立其制备的标准流程是Tregs开展临床应用的前提。
造血干细胞(Hematopoieticstemcells,HSCs)是血液系统中的成体干细胞,是一个异质性的群体,具有长期自我更新的能力和分化成各类成熟血细胞的潜能。在生理环境下,造血干细胞可募集在胸腺中,并在其环境刺激下,经历增殖、定向分化、TCR重排、β选择、阳性选择和阴性选择等复杂发育过程,最终形成一个具有高度多样性的T细胞库。胸腺内T细胞发育包括DN(双阴)、DP(双阳)和SP(单阳)三个主要阶段,DN阶段又可以分为DN1-4四个不同阶段,其表面标志物分别为:LinCD25-CD44+、LinCD25+CD44+、 LinCD25+CD44-、LinCD25-CD44-,DP细胞其表面标志物分别为:CD3+CD4+CD8+,SP细胞其表面标志物分别为:CD3+CD4-CD8+或CD3+CD4+CD8-。90年代中期,国际上就有了开展造血干细胞向T淋巴细胞分化的研究,但均需要运用胸腺上皮细胞加入刺激,而胸腺上皮细胞获得困难,存在伦理问题,遂无深入研究报道。近年来,多家团队建立了无胸腺细胞的T细胞诱导方案,取得了较好的诱导效果。Pawelec等建立了一种限制性稀释的无性培养体系,该体系添加flt-3配基、IL-3、干细胞因子(SCF)、IL-2等细胞因子,支持 CD34干细胞在缺乏胸腺基质的环境下向T细胞分化,进一步验证显示在有丝分裂原刺激下可产生增殖反应,提示其为成熟的T细胞;Sanchez等则从脐血中分离出一种特异性细胞亚群,可诱导CD34在SCF与IL-7的刺激下转化为CD4+CD8+CD45RA+T细胞。然而,以上所获得的T细胞不能进一步分化为具有免疫调节功能的T辅助细胞(Tregs,Th2等),其原因与缺乏胸腺基底细胞的信号刺激有关。
故现需要建立有效的制备造血干细胞来源Tregs的方法,来解决上述问题。
发明内容
本发明克服了现有技术中的不足,提供了一种体外诱导造血干细胞向调节性T细胞分化的方法,利用该方法产生的调节性T细胞数量多且具有较强的免疫调节功能,不仅可用于Tregs的基础研究,也可作为良好的免疫抑制剂使用。
本发明的目的通过下述技术方案予以实现。
一种体外诱导造血干细胞向调节性T细胞分化的方法,具体步骤如下:
第一步,采集血液;
第二步,对血液进行分离、分选获得到CD34+、CD38+和CD39+;
第三步,选择所述第二步的残留细胞,分选获得CD14+细胞,对该CD14+细胞进行扩增,得到大量的DC细胞;
第四步,对所述第二步中分选得到的CD34+、CD38+和CD39+进行第一次诱导;
第五步,在所述第四步加入所述第三步中的DC细胞进行第二次诱导,得到CD4+、CD25+、 Foxp3+调节性T细胞;
第六步,运用流式分选CD3+、CD4+、CD127-和CD39+获得高纯度的调节性T细胞,对调节性T细胞进行刺激、培养扩增,直至细胞数达到目的扩增量,得到CD4+、CD25+、Foxp3+调节性T细胞。
优选地,所述第二步中对血液进行分离的具体方法如下:
步骤一,运用2倍生理盐水稀释血液,再向20ml人淋巴细胞分离液上缓慢加入稀释后的血液25ml,在4℃以1500-2000r/min离心25min,吸取离心后中间白色的细胞层即可得到外周血的淋巴细胞;
步骤二,运用流式抗体染色CD34、CD38、CD39,再将所述步骤一中的外周血的淋巴细胞放入流式细胞分选仪分选获得CD34+、CD38+和CD39+细胞。
由上述任一方案优选地是,所述第三步中获得DC细胞的方法为:
步骤一,选择所述第二步的残留细胞,运用流式抗体染色CD14,再将PBMC放入流式细胞分选仪分选获得CD14+细胞;
步骤二,对CD14+细胞进行30Gy辐照;
步骤三,以0.5-1.0X106/ml细胞浓度接种于培养盘中,加入1000U/ml GM-CSF,以及 1000U/ml IL-4进行刺激6天完成扩增,获得DC细胞。
由上述任一方案优选地是,所述第四步中第一次诱导的方法为:对分选所得的CD34+、 CD38+和CD39+细胞进行刺激,加入胸腺素α1、IL-2、IL-3、TGF-β培养14-20天。
由上述任一方案优选地是,所述第四步中的培养基为α-MEM培养基中添加青霉素100U/ml、链霉素100μg/ml和50mM二羟基乙醇配制而成。
由上述任一方案优选地是,所述第四步中加入胸腺素α1的浓度为40ng/ml。
由上述任一方案优选地是,所述第四步中加入IL-2的浓度为100U/ml,IL-3的浓度为20ng/ml,TGF-β的浓度为100ng/ml。
由上述任一方案优选地是,所述第五步中第二次诱导的方法为:
步骤一,所述第四步中诱导第14天,加入辐照处理的DC细胞和IL-2、IL-3、IL-15、TGF-β以及全反式维甲酸atRA重新刺激,培养9-12日;
步骤二,收集所述步骤一培养后的细胞,得到CD4+、CD25+、Foxp3+调节性T细胞。
由上述任一方案优选地是,所述第五步的步骤一中,所述第四步中诱导14天后的细胞与DC细胞比例为10:1。
由上述任一方案优选地是,所述第五步的所述步骤一中培养的具体方法:每三天计算细胞数并增加培养基,从而保持细胞浓度在0.5X106/ml,同时需重新加入细胞因子以维持浓度。
由上述任一方案优选地是,所述第五步中培养基由完全RPMI-1640培养基中添加青霉素100U/ml、链霉素100μg/ml、2mM左旋谷氨酸、10mM 4-羟乙基哌嗪乙磺酸、0.1mM 非必须氨基酸、1mM丙酮酸钠和50mM二羟基乙醇配制而成。
由上述任一方案优选地是,所述第五步中加入IL-2的浓度为100U/ml、IL-3的浓度为20ng/ml、IL-15的浓度为10ng/ml、TGF-β的浓度为100ng/ml、10nM atRA。
由上述任一方案优选地是,所述第六步对高纯度的调节性T细胞进行进行刺激、培养扩增的具体方法为:加入辐照处理的DC细胞和IL-2、IL-15、atRA和TRAF6,培养直至细胞数达到目的扩增量。
由上述任一方案优选地是,所述第六步中培养的具体方法:每三天计算细胞数并增加培养基,从而保持细胞浓度在0.5X106/ml,同时需重新加入细胞因子以维持浓度。
由上述任一方案优选地是,所述第六步中加入IL-2的浓度为100U/ml、IL-15的浓度为10ng/ml、10nM atRA、TRAF6的浓度为10ng/ml。
本发明的有益效果为:
本发明采用人外周血中分离CD34+、CD38+和CD39+细胞,加入胸腺素α1、IL-2、IL-3、IL-15、TGF-β、atRA、TRAF6以及辐照后DC细胞,最终诱导人的造血干细胞成为具有免疫抑制功能的调节性T细胞,其作用是CD39+造血干细胞不易分化为Tregs,同时该细胞亚群影响T细胞分化得率。
IL-15、TGF-β、atRA、TRAF6不仅参与了T细胞的分化,还能够促进Tregs的生成,辐照的DC细胞提供了类似胸腺基底细胞的作用,同时为T细胞的激活分化提供了有效的(TCR)信号通路,最终达到增加Foxp3的转录的目的。胸腺素α1浓度为40ng/ml,高浓度胸腺素α1可建立胸腺环境,促进Tregs的分化形成,TRAF6可稳定并提高Tregs得率。
附图说明
图1为分化方案流程图;
图2为磁珠Tregs与分化所得Tregs体外扩增数量对比图;
图3为磁珠Tregs与分化所得Tregs扩增中CD25,Foxp3双阳性细胞数;
图4为磁珠Tregs与分化所得Tregs对T细胞的抑制效果统计图;
图5为磁珠Tregs与分化所得Tregs对T细胞的抑制效果流式图;
图6为磁珠Tregs与分化所得Tregs对LPS刺激的T细胞细胞因子表达的抑制效果统计图;
图7为异种移植物抗宿主病的生存情况图;
图8为异种移植物抗宿主病的体重变化图;
图9为异种移植物抗宿主病的病理检测图。
具体实施方式
下面通过具体的实施例对本发明的技术方案作进一步的说明。
实施例一
材料:人外周血。
仪器:流式细胞分选仪,流式细胞仪(BD公司,型号:Vantage SE)。
试剂:流式抗体(CD3,CD4,CD34,CD38,CD39,Foxp3等)购自eBioscience,rhIL-2(加入后最终浓度为100IU/ml),rhIL-15(10ng/ml),atRA(加入后最终浓度为10nM)购自惠氏制药。培养基1由α-MEM培养基中添加青霉素100U/ml,链霉素100μg/ml和50mM 二羟基乙醇配制而成。培养基2由完全RPMI-1640培养基中添加100U/ml青霉素,100u g/ml链霉素,2mM左旋谷氩酸,10mM 4-羟乙基哌嗪乙磺酸,0.1mM非必需氨基酸,1mM 丙酮酸钠(以上购于BioSource International公司)和50uM二羟基乙醇(购于Sigma Aldrich公司)配制而成。
如图1实验步骤如下:
1.1体外分化干细胞以获得调节性T细胞
第一步,采集:采用肝素抗凝常规采血手段采集血液
第二步,分离:运用2倍生理盐水稀释血液,再向20ml人淋巴细胞分离液(购于上海欧韦达仪器科技有限公司)上缓慢加入稀释后的血液25ml,在4度以1500-2000转/ 分离心25分钟,吸取离心后中间白色的细胞层即可得到外周血的淋巴细胞(PBMC),运用流式抗体染色CD34、CD38、CD39,再将PBMC放入流式细胞分选仪分选获得CD34+、CD38+和CD39+细胞。
第三步,DC细胞准备:选择第二步的残留细胞,运用流式抗体染色CD14,再将PBMC放入流式细胞分选仪分选获得CD14+细胞,DC细胞以0.5-1.0X106/ml细胞浓度接种于培养盘中,加入GM-CSF(1000U/ml),IL-4(1000U/ml)刺激6天。
第四步,第一次刺激:第一天,向所述第一步中获得的CD34+、CD38+和CD39+加入胸腺素α1(40ng/ml),IL-2(100U/ml),IL-3(20ng/ml),TGF-β(100ng/ml)培养 14-20天,每三天计算细胞数,并根据细胞密度分盘,补充培养基以及以上细胞因子(培养基1)。
培养基1为α-MEM培养基中添加青霉素100U/ml,链霉素100μg/ml和50mΜ二羟基乙醇配制而成
第五步,第二次刺激:以上所得细胞加入胸腺素α1(40ng/ml),IL-2(100U/ml),IL-3(20ng/ml),IL-15(10ng/ml),TGF-β(100ng/ml)和atRA(10mM),辐照处理的 DC细胞(10:1)培养9-12天,每三天计算细胞数,并根据细胞密度分盘,补充培养基以及以上细胞因子(培养基2)。
培养基2由完全RPMI-1640培养基中添加青霉素100U/ml,链霉素100μg/ml,2mM左旋谷氨酸,10mM 4-羟乙基哌嗪乙磺酸,0.1mM非必须氨基酸,1mM丙酮酸钠和50mΜ二羟基乙醇配制而成。
第六步,第三次刺激:以上所得细胞加入IL-2(100U/ml),IL-15(10ng/ml),TRAF6(10ng/ml)和atRA(10mM),辐照处理的DC细胞(10:1)培养9天,每三天计算细胞数,并根据细胞密度分盘,补充培养基以及以上细胞因子(培养基2)。
使用细胞前,将上述细胞在含有10%FBS和rh-IL-2(1000IU/ml)的RPMI 1640培养基中休息24小时,收集上述细胞,即为调节性T细胞。
培养基2由完全RPMI-1640培养基中添加青霉素100U/ml,链霉素100μg/ml,2mM左旋谷氨酸,10mM 4-羟乙基哌嗪乙磺酸,0.1mM非必须氨基酸,1mM丙酮酸钠和50mΜ二羟基乙醇配制而成。
如图2所示运用CD4、CD25、CD127磁珠分选人外周血的CD4+、CD25+、CD127-Treg 细胞,加入CD3/CD28磁珠,IL-2以扩增Tregs。培养第0,7,14天后,检测细胞扩增数量差异。分化所得Treg则选取第三次分化为第0天进行扩增,在相应时间点比较细胞数量差异。结果显示HSC-Tregs得率明显高于外周血扩增来源Tregs。
如图3所示运用CD4、CD25、CD127磁珠分选人外周血的CD4+、CD25+、CD127-Treg 细胞,加入CD3/CD28磁珠,IL-2以扩增Tregs。分化所得Treg则选取第三次分化为第0 天进行扩增,在相应时间点比较CD25+、Foxp3+细胞比例差异。结果显示细胞群内的Tregs 纯度无差异。
1.2分化所得调节性T细胞的分析鉴定
1.2.1将本发明所得的调节性T细胞,anti-CD3/CD28磁珠诱导形成的调节性T细胞按照1:5,1:10,1:20的比例与CFSE荧光标记的T细胞共培养,结果如图四4,图5所示,图3所得的磁珠Tregs或分化所得Tregs与CFSE标记的T细胞于体外共培养,加入抗CD3扩增磁珠,检测相应Tregs对T细胞扩增效率的抑制效果。分化所得Tregs表现出比拟传统方案诱导的调节性T细胞的抑制T细胞增殖的能力,同时在第浓度下,该细胞依旧拥有一定的调节功能。结论:分化所得Tregs具有与传统方案扩增类似的免疫调节能力。
1.2.2将本发明所得的调节性T细胞,anti-CD3/CD28磁珠诱导形成的调节性T细胞与LPS刺激的外周血淋巴细胞共培养三天,并流式检测细胞因子,结果如图6所示,分化所得Tregs在炎症环境下具有一定的稳定性,少量细胞向Th1,Th17细胞的分化。结论:分化所得Tregs具有与磁珠诱导的诱导性调节性T细胞(iTreg)类似的稳定性。
1.2.3将上述方法获得的Tregs单独,或者联合同种异体的荧光燃料CFSE标记的T细胞一起经尾静脉注入SCID小鼠体内,本方法所获得的的调节性T细胞自身并不致病,同时能够抑制效应T细胞的增殖,延缓或者预防GVHD的发生。如图7、图8、图9所示:对照组肝脏出现明显的肝硬化小叶,肾脏出现明显的肾小管坏死和炎症,肺部出现明显的纤维化,而以上病理变化均未出现在调节性T细胞治疗组。可见调节性T细胞具有体内抑制功能,且无毒副作用。
1.3转化研究应用举例
采人外周血,提取造血干细胞后运用上述方案分化调节性T细胞,建立人源化皮肤移植小鼠模型,并用以上细胞进行回输,剂量为5X106/只。观察细胞体内存活周期和毒副作用。注射后的Tregs在体内能存活30天-50天,本身未引起发热,过敏等不良反应,同时有效减轻了皮肤移植损伤。
由以上实验得出本发明的优点如下:
(1)造血干细胞分化所得调节性T细胞具有明显的抑制T细胞的增生;
(2)造血干细胞分化所得调节性T细胞本身没有明显的毒副作用,具有体内长期的保护作用能力。
(3)造血干细胞分化所得调节性T细胞可以代替免疫抑制剂或者减少免疫抑制剂的使用剂量,用于器官移植后期免疫维持治疗,同时可以用于自身免疫性疾病患者或I型糖尿病的治疗,这将是器官移植免疫治疗史上里程碑性的突破。
以上对本发明的一个实施例进行了详细说明,但所述内容仅为本发明的较佳实施例,不能被认为用于限定本发明的实施范围。凡依本发明申请范围所作的均等变化与改进等,均应仍归属于本发明的专利涵盖范围之内。
Claims (10)
1.一种体外诱导造血干细胞向调节性T细胞分化的方法,其特征在于:具体步骤如下:
第一步,采集血液;
第二步,对血液进行分离、分选获得到CD34+、CD38+和CD39+;
第三步,选择所述第二步的残留细胞,分选获得CD14+细胞,对该CD14+细胞进行扩增,得到大量的DC细胞;
第四步,对所述第二步中分选得到的CD34+、CD38+和CD39+进行第一次诱导;
第五步,在所述第四步加入所述第三步中的DC细胞进行第二次诱导,得到CD4+、CD25+、Foxp3+调节性T细胞;
第六步,收集第五步细胞运用流式分选CD3+、CD4+、CD127-和CD39+获得高纯度的调节性T细胞,对调节性T细胞进行刺激、培养扩增,直至细胞数达到目的扩增量,得到CD4+、CD25+、Foxp3+调节性T细胞。
2.根据权利要求1所述的体外诱导造血干细胞向调节性T细胞分化的方法,其特征在于:所述第二步中对血液进行分离的具体方法如下:
步骤一,运用2倍生理盐水稀释血液,再向20ml人淋巴细胞分离液上缓慢加入稀释后的血液25ml,在4℃以1500-2000r/min离心25min,吸取离心后中间白色的细胞层即可得到外周血的淋巴细胞;
步骤二,运用流式抗体染色CD34、CD38、CD39,再将所述步骤一中的外周血的淋巴细胞放入流式细胞分选仪分选获得CD34+、CD38+和CD39+细胞。
3.根据权利要求1所述的体外诱导造血干细胞向调节性T细胞分化的方法,其特征在于:所述第三步中获得DC细胞的方法为:
步骤一,选择所述第二步的残留细胞,运用流式抗体染色CD14,再将PBMC放入流式细胞分选仪分选获得CD14+细胞;
步骤二,对CD14+细胞进行30Gy辐照;
步骤三,以0.5-1.0X106/ml细胞浓度接种于培养盘中,加入1000U/ml GM-CSF,以及1000U/ml IL-4进行刺激6天完成扩增,获得DC细胞。
4.根据权利要求1所述的体外诱导造血干细胞向调节性T细胞分化的方法,其特征在于:所述第四步中第一次诱导的方法为:对所述第一步中分选所得的CD34+、CD38+和CD39+细胞进行刺激,加入胸腺素α1、IL-2、IL-3、TGF-β培养14-20天。
5.根据权利要求4所述的体外诱导造血干细胞向调节性T细胞分化的方法,其特征在于:所述第四步中的培养基为α-MEM培养基中添加青霉素100U/ml、链霉素100μg/ml和50mM二羟基乙醇配制而成。
6.根据权利要求4所述的体外诱导造血干细胞向调节性T细胞分化的方法,其特征在于:所述第四步中加入胸腺素α1的浓度为40ng/ml。
7.根据权利要求1所述的体外诱导造血干细胞向调节性T细胞分化的方法,其特征在于:所述第五步中第二次诱导的方法为:
步骤一,所述第四步中诱导第14天,加入辐照处理的DC细胞和IL-2、IL-3、IL-15、TGF-β以及全反式维甲酸atRA重新刺激,培养9-12日;
步骤二,收集所述步骤一培养后的细胞,得到CD4+、CD25+、Foxp3+调节性T细胞。
8.根据权利要求7所述的体外诱导造血干细胞向调节性T细胞分化的方法,其特征在于:所述第五步的所述步骤一中培养的具体方法:每三天计算细胞数并增加培养基,从而保持细胞浓度在0.5X106/ml,同时需重新加入细胞因子以维持浓度。
9.根据权利要求7所述的体外诱导造血干细胞向调节性T细胞分化的方法,其特征在于:所述第五步中培养基由完全RPMI-1640培养基中添加青霉素100U/ml、链霉素100μg/ml、2mM左旋谷氨酸、10mM 4-羟乙基哌嗪乙磺酸、0.1mM非必须氨基酸、1mM丙酮酸钠和50mM二羟基乙醇配制而成。
10.根据权利要求1所述的体外诱导造血干细胞向调节性T细胞分化的方法,其特征在于:所述第六步对高纯度的调节性T细胞进行进行刺激、培养扩增的具体方法为:加入辐照处理的DC细胞和IL-2、IL-15、atRA和TRAF6,培养直至细胞数达到目的扩增量。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110308242.7A CN112852731A (zh) | 2021-03-23 | 2021-03-23 | 一种体外诱导造血干细胞向调节性t细胞分化的方法 |
PCT/CN2021/099398 WO2022198805A1 (zh) | 2021-03-23 | 2021-06-10 | 一种体外诱导造血干细胞向调节性t细胞分化的方法 |
ZA2022/11512A ZA202211512B (en) | 2021-03-23 | 2022-10-20 | An in vitro method for inducing the differentiation of hscs into tregs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110308242.7A CN112852731A (zh) | 2021-03-23 | 2021-03-23 | 一种体外诱导造血干细胞向调节性t细胞分化的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112852731A true CN112852731A (zh) | 2021-05-28 |
Family
ID=75992427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110308242.7A Withdrawn CN112852731A (zh) | 2021-03-23 | 2021-03-23 | 一种体外诱导造血干细胞向调节性t细胞分化的方法 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN112852731A (zh) |
WO (1) | WO2022198805A1 (zh) |
ZA (1) | ZA202211512B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022198805A1 (zh) * | 2021-03-23 | 2022-09-29 | 细胞谷(南京)生物科技有限公司 | 一种体外诱导造血干细胞向调节性t细胞分化的方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024077158A1 (en) * | 2022-10-05 | 2024-04-11 | Garuda Therapeutics, Inc. | Pluripotent stem cell-derived t cell populations and progenitors thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1391504A1 (en) * | 2002-08-12 | 2004-02-25 | Gerold Schuler | CD4+ CD25- T cells and Tr1-like regulatory T cells |
CN101603030B (zh) * | 2009-07-14 | 2011-05-25 | 吕凌 | 一种体外扩增调节性t细胞的方法 |
CN104651309A (zh) * | 2015-02-04 | 2015-05-27 | 中山大学孙逸仙纪念医院 | 人外周血CD4+CD25+Foxp3+调节性T细胞的分选扩增方法 |
CN108004208A (zh) * | 2017-12-01 | 2018-05-08 | 南京爱瑞生物科技有限公司 | 一种体外诱导抗原特异性t细胞的方法 |
CN111593023A (zh) * | 2020-01-14 | 2020-08-28 | 河南省银丰生物工程技术有限公司 | 一种T-reg细胞的体外培养方法 |
CN112852731A (zh) * | 2021-03-23 | 2021-05-28 | 细胞谷(南京)生物科技有限公司 | 一种体外诱导造血干细胞向调节性t细胞分化的方法 |
-
2021
- 2021-03-23 CN CN202110308242.7A patent/CN112852731A/zh not_active Withdrawn
- 2021-06-10 WO PCT/CN2021/099398 patent/WO2022198805A1/zh active Application Filing
-
2022
- 2022-10-20 ZA ZA2022/11512A patent/ZA202211512B/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022198805A1 (zh) * | 2021-03-23 | 2022-09-29 | 细胞谷(南京)生物科技有限公司 | 一种体外诱导造血干细胞向调节性t细胞分化的方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2022198805A1 (zh) | 2022-09-29 |
ZA202211512B (en) | 2022-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2878726C (en) | Acellular pro-tolerogenic compositions and process for making same | |
US20210371820A1 (en) | Method for amplifying antigen-specific regulatory t cells in vitro | |
EP0966523A1 (en) | Method for the production of selected lymphocytes | |
CN108588022B (zh) | 体外培养富集人cd4+和cd8+ tcm细胞的方法 | |
CN112852731A (zh) | 一种体外诱导造血干细胞向调节性t细胞分化的方法 | |
CN115710576A (zh) | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 | |
US9169461B2 (en) | Use of apoptotic cells ex vivo to generate regulatory T cells | |
CN113046313A (zh) | 用于高效诱导扩增人体外周血杀伤性免疫细胞的组合物、试剂盒以及该免疫细胞的培养方法 | |
WO1994016715A1 (en) | Selective cell proliferation | |
Yu et al. | Regulatory T cell therapy following liver transplantation | |
CN112608896A (zh) | 一种nk细胞的培养方法及其应用 | |
US20230015932A1 (en) | Method of generation of lympho-myeloid niches | |
CN111172110B (zh) | 一种脐带血cik细胞的培养方法 | |
WO2014136845A1 (ja) | 成熟樹状細胞集団の製造方法 | |
CN109535241B (zh) | Dc-cik共培养细胞及其制备方法、致敏抗原和应用 | |
HUE028895T2 (en) | Co-differentiation and activation of monocytes from allogeneic donors to provide inflammatory dendritic cells | |
CN113637636B (zh) | 一种提高体外培养初始t细胞比例的方法 | |
CN113943704A (zh) | 一种肿瘤新生抗原特异性t细胞的制备方法 | |
CN108690830B (zh) | 一种高效扩增nkt细胞的方法 | |
CN114958740B (zh) | 体外培养富集人nk细胞的方法 | |
US20200147133A1 (en) | Combination Therapy of Acellular Pro-Tolerogenic and Pro-Inflammatory Preparations for Modulating the Immune System | |
CN117126809A (zh) | 体外诱导nk细胞扩增试剂盒及体外诱导nk细胞扩增方法 | |
CN114657124A (zh) | 一种对肿瘤细胞具有高杀伤能力的复合型免疫细胞制备方法 | |
KR20210067776A (ko) | 냉동 및 해동 과정을 포함하는 자연살해세포의 대량생산방법 | |
CN115232854A (zh) | 一种源细胞的筛选方法、源细胞、细胞库及产品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210528 |